Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
Status:
Not yet recruiting
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy)
+ lurbinectedin as switch maintenance therapy for mUC following stable or responding disease
on 4-6 cycles of first line platinum-based chemotherapy